Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02898116
Title A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Ludwig Institute for Cancer Research
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Ensartinib

Ensartinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST